Introduction
The nuclear factor of k-light polypeptide gene enhancer in B lymphocytes (NF-kB) was discovered in 1986 and consists of a family of five proteins that are critical in the regulation of gene transcription in most human cells. 1 The biology of these proteins has been extensively reviewed elsewhere. 2, 3 Briefly, NF-kB is restrained in the cytoplasm by an inhibitor of NF-kB (IkB). It can be released from IkB through phosphorylation of the IkB by an IkB kinase (IKK). This facilitates the ubiquitination and degradation of IkB, allowing for the translocation of NF-kB dimers to the nucleus where gene transcription can be promoted. The canonical IKK complex consists of at least three proteins, IKK-a, IKK-b and IKK-g. IKK-g is also known as the NF-kB essential modulator, or NEMO. Increasingly, inherited immunodeficiency syndromes associated with the dysregulation of NF-kB are being described, 4 of which ectodermal dysplasia with immunodeficiency (ED-ID) was the first defined on a molecular level. ED-ID is caused by genetic mutations altering the function of the IKK complex, with IkBa and NEMO mutations having been described. NEMO ED-ID is an X-linked syndrome caused by a hypomorphic mutation in the IKBKG gene. 5 Boys affected with NEMO ED-ID have severely impaired host defense, are prone to serious bacterial infections, pneumocystis and DNA viruses, and have susceptibility to atypical mycobacteria. [5] [6] [7] [8] [9] [10] [11] This increased infectious risk likely arises secondary to impaired B-cell functions, T-cell receptor signaling, natural killer cell cytotoxicity and toll-like receptor-mediated responses. Thus, ED-ID reflects a combined defect of both innate and adaptive immunity.
Although the infectious complications are generally considered the most immediately life threatening, NF-kB signaling defects also increase the risk of inflammatory diseases, in particular inflammatory colitis. 9 Colitis in the context of ED-ID can be debilitating, difficult to control and life threatening. 12 Hematopoietic SCT (HSCT) is the best-accepted curative therapy for inherited immunodeficiency syndromes. HSCT from HLA-identical donors has been used to treat SCID since 1968, 13 and the introduction of donor T-cell depletion in 1981 14 allowed for the use of HLA-mismatched stem-cell sources in the successful treatment of SCID. 15, 16 Since that time, HSCT from HLA-identical, matched or mismatched donors has been used to treat a multitude of hereditary immunodeficiencies. 17 Although the extensive combined immunodeficiency in ED-ID would appear amenable to HSCT-mediated correction, the disease-causing mutations are not exclusively hematopoietic. Thus, the effects of persistently expressed mutations in somatic cells need to be considered in the context of HSCT therapy and immune reconstitution. There have been only three previously reported cases of patients with ED-ID undergoing allogeneic HSCT [18] [19] [20] ( Table 1) . None describes disease-specific difficulties and some report clinical success without persistent complications, thus suggesting that HSCT may provide substantial benefit to patients with ED-ID. We provide outcomes of allogeneic HSCT for the correction of the immunodeficiency associated with ED-ID in three previously unreported patients. Unanticipated post-HSCT complications in these patients highlight special disease features that may impact outcome.
Patients and methods
This is a descriptive retrospective study, which was approved by the Institutional Review Board at the Children's Hospital of Philadelphia under the exempt status. Three centers that had performed hematopoietic stem cell transplants in patients with ED-ID were identified and a questionnaire was sent to physicians directly responsible for the care of those patients.
Results
Three pediatric HSCT centers completed forms regarding ED-ID patients treated with HSCT in an effort to cure their immunodeficiency. Patients were all treated in this decade. One patient is alive at present, and two died in the course of their immune reconstitution. The clinical details of the HSCT for all three patients are shown in Table 2 , and pertinent clinical data are detailed below.
The first patient developed recurrent fever, diarrhea, failure to thrive and diffuse erythema with desquamation as a neonate. This course was suspected to result from GVHD secondary to maternal-fetal transfusion, but evaluation revealed no maternal cells or DNA. He was, however, treated with corticosteroids and cyclosporine for immunosuppression. Suspicion of a heritable dysregulation of immunity led to an immunological assessment notable for hypogammaglobulinemia with normal B-and T-cell numbers. Subsequent genetic analysis demonstrated a hypomorphic NEMO mutation that has previously been defined to cause disease in other ED-ID patients. 5 Specifically, it revealed an insertion at 1167 (1167insC) of the IKBKG gene predicted to result in a frameshift at P389 (his mother was a carrier of the mutation, although his two sisters were not). 21 Secondary to recurrent infections, persistent diarrhea, failure to thrive and the known immunodeficiency-associated mutation, he was referred for an HLA-identical HSCT at 6 months of age (Table 2) . Following HSCT, he achieved neutrophil engraftment (first day of ANC 4500/ml Â 3 days) at day þ 17, but subsequently developed rash and worsening diarrhea. A colonic biopsy demonstrated occasional apoptotic figures. Although the rash and colonic biopsy findings could have been consistent with GVHD, the rash was similar to his neonatal rash, and the diarrhea persisted following the resolution of other GVHD-like symptoms. Thus, the underlying NEMO dysregulation may have been responsible for these findings. He achieved maximal donor T-cell chimerism of 53% at day þ 77, which then declined to 52% on day þ 110, and 38% on day þ 158. Secondary to the declining donor T-cell chimerism, he underwent a second HSCT from the same donor. There were no infectious complications associated with the second transplant. He achieved neutrophil engraftment at day þ 16, and maximal donor T-cell chimerism of 99% at day þ 100, followed by declining T-cell chimerism (91% at day þ 126, and 81% at day þ 133). Through manipulation of immunosuppression, the T-cell chimerism increased to 98% at day þ 307. At approximately 1 year post transplant, the child has had appropriate development, but had persistent abnormal dentition and rashes, poor weight gain and diarrhea requiring G-tube feedings.
As a newborn, the second patient developed vomiting and failure to thrive requiring hospitalization at 5 weeks of age, and repeated subsequent hospitalizations for continued failure to thrive, vomiting, diarrhea and dehydration. He also developed scrotal and lower extremity lymphedema. After conical incisor eruption at 13 months of age, he was diagnosed with ED. His course was further complicated by a cerebral venous sinus thrombosis, which was presumed to be secondary to dehydration. He developed multiple invasive bacterial infections, as well as several episodes of Clostridium difficile ( þ ) colitis and intestinal mycobacterium avium complex. An immunological assessment identified elevated IgM levels, impaired specific antibody responses and normal B-and T-cell numbers. Genetic analysis defined an intervening sequence (IVS) 6 þ 5 G4A mutation in the NEMO gene, which has been previously described as causing ED-ID in a large family cohort. 22 The mutation was also identified in the patient's mother. Secondary to persistent infections, colitis and failure to thrive, he was referred for a matched unrelated donor BMT at 3.5 years of age (Table 2) . His post transplant course was complicated by a frontal-parietal hemorrhage with seizure, and bacteremia with multiple organisms, including Enterobacter cloacae, Staphylococcus haemolyticus, Candida parapsolosis and Candida krusei. Engraftment was delayed, and an ANC greater than 500/ml was never achieved. Bone marrow aspirate and biopsy on day þ 24 demonstrated 65% donor chimerism but was extremely hypocellular. Chimerism assays sent from peripheral blood showed 95% donor chimerism on days þ 31 and þ 39, with a subsequent decrease to 90% donor chimerism at day þ 42. Owing to very poor myeloid engraftment and the declining donor chimerism, he underwent a peripheral stem cell boost from the same donor on day þ 53 (Table 2) . He achieved neutrophil engraftment at day þ 12 from the peripheral stem cell boost, and 100% donor chimerism at day þ 16. He then maintained 100% donor chimerism. His second post transplant course was complicated by persistent diarrhea and poor weight gain. Colonic biopsies pre-and post-HSCT demonstrated no improvement in intestinal inflammation, even following adequate engraftment. He contracted parainfluenza type III and developed adult respiratory distress syndrome, which progressed to respiratory failure and death on day þ 314.
The third patient developed chronic diarrhea associated with failure to thrive shortly after birth, as well as recurrent episodes of bacterial sepsis and infection with Pneumocystis jiroveci. An immunological evaluation demonstrated normal immunoglobulin levels and normal B-and T-cell numbers and lymphocyte subsets. Genetic analysis revealed a new nonsense mutation in the IKBA gene resulting in a STOP codon at Glu14. Secondary to persistent diarrhea, failure to thrive, sepsis and immune deficiency, he was referred for a partially matched unrelated donor cord blood transplant. Following his first transplant, he never achieved adequate neutrophil engraftment, and ultimately had autologous reconstitution. At day þ 100, he underwent a second HSCT (Table 2 ) with a second partially matched unrelated cord blood. His peritransplant course was complicated by fatal bacterial sepsis with a resistant strain of Pseudomonas aerugenosa at day þ 5 from receiving his stem cells.
Discussion
Ectodermal dysplasia with immunodeficiency secondary to hypomorphic NEMO or hypermorphic IkBa mutations frequently presents with life-threatening infections. 7, 9, 23 Although many congenital immunodeficiencies with severe phenotypes can be definitively cured with HSCT, there have been only three reports of patients with ED-ID who underwent HSCT (Table 1 ). The first report described the myeloablative, HLA-matched unrelated donor transplant for a patient with ED-ID, lymphedema and osteopetrosis associated with a NEMO mutation who died of severe hepatic toxicity shortly after conditioning. 19 The second report described a successful haploidentical, myeloablative transplant of a patient with ED-ID associated with a mutation in the IKBA gene. 18 That child has been followed for 7 years, and has normal immune reconstitution, although other aspects of the ED-ID syndrome were not corrected by the HSCT. The third report described the successful correction of immunodeficiency associated with a NEMO mutation using a cord blood transplant following a reduced-intensity conditioning regimen. 20 In this report, we describe an additional three patients with ED-ID who underwent allogeneic HSCT. There were two prominent, consistent problems that we noted in this collective experience: first, these patients had difficulty achieving adequate engraftment; second, and perhaps most importantly, these patients had no improvement in the associated manifestations of their disease. In particular, the colitis was not improved by HSCT or worsened (second patient). Supporting this observation, patient 1 did not have severe colitis before transplant, but developed it following transplant, and there was also no improvement in the intestinal inflammation in patient 2 following engraftment. The potential for these patients to develop worsening colitis following transplant was underscored mechanistically by a recent publication describing a murine model of intestinal epithelial NEMO deficiency. 24 The authors described impaired intestinal epithelial integrity in mice with targeted deficiency of NEMO in epithelial cells of the intestine. The impaired intestinal integrity resulted in translocation of gut bacteria and concomitant aggregation of immune cells in the intestinal wall. The mice in this study had fully functional immune systems and developed profound colitis. Importantly, the authors found that when the mice were rendered immunodeficient by genetic crossing with mice having defective Toll-like receptor signaling, the colitis phenotype was not present. These observations suggest that the correction of the immune deficiency in patients with NEMO deficiency or IkBa hypermorphism potentially could exacerbate preexisting colitis, or even augment an otherwise subclinical predisposition to colitis. It is possible that the colitis in these patients pre-HSCT is less severe secondary to defective immunity, resulting in minimal local production of inflammatory cytokines in the intestine. By correcting the immune deficit, normally functioning immune cells would be fully enabled to recognize and respond to gut wall-invading bacteria. As a consequence, these immune cells would release increased inflammatory cytokines, with resultant worsening of the chronic inflammatory colitis.
The outcomes of the patients reported here, as well as the patient reported earlier by Dupuis-Girod et al., 19 suggest a barrier to engraftment in patients with life-threatening immunodeficiency associated with ED-ID. The dysregulation of NF-kB resulting in cellular dysfunction is not restricted to the hematopoietic and immune tissues and suggests several possibilities as to the nature of the difficulties in obtaining adequate engraftment in patients with ED-ID: (1) it may be secondary to end-organ damage already present before transplant; (2) secondary to an abnormality in the marrow microenvironment; or (3) more rapid rejection from the inflammatory component of the disease.
Although there is a paucity of data in the literature to support the use of HSCT for treatment of immunodeficiency associated with ED-ID, the data from the patients reported to date suggest caution when considering this option for a patient with ED-ID. An informed discussion with the family must include the understanding that the nonimmune constitutional manifestations of the disease will not be corrected by HSCT, and that the inflammatory colitis could potentially worsen with the correction of the immune deficits. There is very limited information regarding the optimal conditioning regimen, but the possibility that an immune or inflammatory component may be responsible for difficulties in achieving adequate engraftment suggests that a fully myeloablative conditioning regimen may be preferable to a reduced intensity regimen. Additionally, the possible existence of other physiological barriers to engraftment, such as an abnormal marrow microenvironment, must be evaluated further. Additional research on the effects of NF-kB dysregulation in the hematopoietic and intestinal milieu is critical, and further studies examining the function of HSCT for patients with ED-ID are needed. Although the immune dysregulation can likely be cured with HSCT if an adequate graft can be achieved, other systemic complications of NF-kB dysregulation will persist, such as worsening colitis. When considering HSCT therapy for patients with ED-ID, the potential for graft rejection as well as the persistent systemic complications must be factors in the decision process.
